RT Journal Article
T1 Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents
A1 Molina-Cuadrado, Emilio
A1 Mateo-Carrrasco, Hector
A1 Collado, Antonio
A1 Martin, Marta Casado
K1 Ribavirin
K1 Direct-acting antiviral
K1 Anaemia
K1 Predictor
K1 Hepatitis C
K1 Peginterferon
K1 Telaprevir
K1 Therapy
K1 Combination
K1 Alpha-2a
AB Objectives Anaemia is the most common side effect associated with ribavirin (RBV). This study intended to assess its incidence and determine its predictive factors in patients with hepatitis C virus on RBV plus direct-acting antiviral agents (DAAs).Methods A retrospective study of patients receiving RBV+DAA was conducted. Serum haemoglobin (Hb) was determined at baseline and monitored 4weekly. Anaemia was defined as a single occurrence of Hb
PB Bmj publishing group
SN 2047-9956
YR 2018
FD 2018-05-01
LK https://hdl.handle.net/10668/24955
UL https://hdl.handle.net/10668/24955
LA en
DS RISalud
RD Apr 10, 2025